Latest LB Pharmaceuticals News & Updates

See the latest news and media coverage for LB Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
LB Pharmaceuticals

Biopharmaceutical company developing therapies for neuropsychiatric diseases

lbpharma.us
Founded year
2015
Company type
Private company
Number of employees
10–60
Industry
Pharmaceuticals

Last updated

Latest news about LB Pharmaceuticals

In short: LB Pharmaceuticals secured $150M in funding, accelerated its Phase 3 schizophrenia trial timeline, and appointed a new clinical lead.

Company announcements

LB Pharmaceuticals

LB Pharmaceuticals announces Phase 2 trial results in JAMA Psychiatry

The Phase 3 NOVA-2 trial is ongoing, with topline data expected in 2027, and LB-102 could be the first US-approved benzamide.

Unlock all announcements with a

Media coverage

Psychiatry Advisor

LB-102 Enters Phase 3 Trial for Schizophrenia Treatment Efficacy - Psychiatry Advisor

LB Pharmaceuticals initiates a phase 3 study of once-daily oral LB-102 to address positive and negative symptoms of schizophrenia.

Unlock all articles with a

Never miss news about LB Pharmaceuticals

Track LB Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

LB Pharmaceuticals competitors & trending companies

Browse news for competitors to LB Pharmaceuticals and other trending companies.